The Cancer Seems Small:
  Is It Safe to Treat Just One Part of the Prostate?

alan partin prostate cancer
Alan Partin

Some people get through cancer, after treatment, by looking at it one way — in the rear-view mirror, as they push the pedal to the floor and race away from it as fast as they can. They don’t want to think about it ever again, and no one can blame them.


Others become interested in the disease, especially if there is a risk — as there is in prostate cancer — that their sons or grandsons might one day face this same cancer. They read everything they can about it. They learn about the research, about new developments in prevention, and screening, and the continuing effort to develop new treatments. Many of them — many of you reading this — even help support the work we do here at the Brady Urological Institute, for which we are profoundly grateful.
prostate cancer board
Committed to helping men beat prostate cancer: The Johns Hopkins Prostate Cancer Advisory Board met recently
in New York City. Members include, from left: William Stutt, Joseph McCann, Salvatore Bommarito, Joseph Rascoff,
Chris Evensen, Norman Peck, Keith Reinhard, and Olin Robison.

Despite their varied backgrounds, they all have one thing in common: They are absolutely committed to curing prostate cancer, and they believe the cure will be discovered here.

And some in this group take it a step farther, with an attitude that might be summed up, as the military expression goes, as, “Not on my watch.” We are very fortunate to have 28 people like this on our Prostate Cancer Advisory Board. Research funds may dwindle, they realize, but research itself will not dwindle — not on my watch. Opportunities may be missed to recruit and hire promising new faculty — but not on my watch. New technology is available, or is being developed, but we can’t afford it. Not on my watch. Discoveries are being made, but it is months or even years before patients can benefit from them. Not on my watch. Not while they have anything to say about it.

These are the people who do a great deal to make things happen at the Brady. They help select recipients for our Patrick C. Walsh Prostate Cancer Research Fund awards, giving scientists with good ideas the help they need to get further funding. Many of their names appear in this publication, in the Founders Circle, and in named scholarships and professorships. Joseph Rascoff is concluding his term as chairman of the Advisory Board, and R. Christian B. Evensen is the new chairman. The leaders on this board come from many different backgrounds — industry, academics,
finance, marketing, real estate, to name a few. Twice a year, they meet with Brady scientists and physicians in urology, pathology, radiation oncology, and medical oncology, and are never farther away than a phone call the rest of the year.

Despite their varied backgrounds, they all have one thing in common: They are absolutely committed to curing prostate cancer, and they believe the cure will be discovered here.
As always, in this issue we are bringing you the latest discoveries happening every day at the Brady; and, as always, there is barely room in these few pages to tap the surface of what’s going on. As many of you already know, you are playing an invaluable role in our work. Our Biorepository (read story), funded with support from the National Institutes of Health, holds nearly 8,000 samples of blood and urine products from men with every stage of prostate cancer. It is a world-class resource, and it has greatly hastened our ability to develop and test new biomarkers.

Although this resource is precious, we don’t hoard it; instead, we share it freely with scientists from around the world who are working toward our same goal — helping men with prostate cancer.

We have made great strides in learning about the genetics of prostate cancer, and we have taken a huge step toward being able to test men before they ever develop cancer to determine their genetic risk (read story).

I hope, as you read this latest issue of Discovery, that you will share in our excitement that great things are happening here to help make lives better for men with prostate cancer and their families.

Best wishes,
Alan W. Partin, M.D., Ph.D.
David Hall McConnell Professor and Director
The Brady Urological Institute

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved. Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287

urology second opinion urology second opinion